Prostaglandin Analogs API Comparison: Misoprostol, Dinoprostone (PGE2), Latanoprost, Bimatoprost, Alprostadil (PGE1) — Market, Application & Export Guide

Five prostaglandin APIs, one decision table. Misoprostol (CAS 59122-46-2) and Alprostadil (CAS 745-65-3) belong to the PGE1 family; Dinoprostone (CAS 363-24-6) is the natural PGE2; Latanoprost (CAS 130209-82-4) and Bimatoprost (CAS 155206-00-1) are PGF2α-series ophthalmic analogs. Same parent scaffold — completely different receptors, indications, stability, compliance exposure and export volumes. Those differences decide the sourcing route, the storage regime and the regulatory dossier for each compound.

1. Five-Way Snapshot: The Core Comparison Table

The five mainstream prostaglandin APIs differ across classification, receptor, core application, stability and trade reality — the five axes on which sourcing decisions in this category turn.

2. PGE Series vs PGF2α Series — Where Buyers Mix It Up

The single most common sourcing error in this category is treating "prostaglandin" as one product family. It is not. In the prostanoid nomenclature, the letter indicates the substitution pattern of the cyclopentane ring and the subscript indicates the number of double bonds in the side chains — and that apparently cosmetic difference rewires the pharmacology.

The three families in practice

• PGE1 series — Misoprostol, Alprostadil. Act primarily through EP receptors (EP1–EP4). Clinically this means smooth-muscle effects: uterine contraction, gastric acid suppression and mucosal protection, and vascular smooth-muscle relaxation. This is the obstetric / gastroprotective / vascular-vasodilation family.
• PGE2 series — Dinoprostone only. The natural ligand, a pan-EP agonist. Same receptor family as PGE1, but an inherently fragile molecule that is used almost exclusively in a local obstetric setting (vaginal gel, insert or pessary) rather than systemically.
• PGF2α series — Latanoprost, Bimatoprost, plus Travoprost, Tafluprost, Unoprostone. Act on the FP receptor. Their defining property in clinical use is local intraocular pressure reduction with essentially no systemic uterine stimulation — which is precisely why the ophthalmic analogs are not interchangeable with the obstetric ones, and why a confusion between them is a documentation problem, not just a purchasing problem.

Why the scaffold drifted in two directions

Left to itself, the natural prostaglandin is a poor drug: it is metabolised within minutes, and it degrades on the shelf. Medicinal chemists solved this in two opposite ways depending on the target organ.

• For systemic and obstetric use, the fix was to stabilise the PGE core as a methyl ester — Misoprostol — creating an orally available, thermostable solid. The ester is hydrolysed in vivo to misoprostol free acid, the active EP agonist.
• For ophthalmic use, the fix was to esterify the PGF2α carboxylic acid with an isopropyl group — Latanoprost — to improve corneal penetration. Corneal esterases then release the active latanoprost acid inside the eye.

Both are prodrug strategies. One is optimised for a swallowed tablet in a tropical clinic; the other for a 2.5 mL eye-drop bottle in a pharmacy fridge. That is the whole story of why these molecules live in different supply chains.

3. CAS Numbers, Molecular Formula & Chemical Identity

Prostaglandin APIs are near-isomeric, and several of these compounds share an identical molecular formula. CAS number and molecular formula are therefore both carried on the specification, because neither alone gives an unambiguous identity.

Identity traps in this API family

• Alprostadil vs Dinoprostone: C₂₀H₃₄O₅ versus C₂₀H₃₂O₅ — a difference of exactly two hydrogens. They look and behave similarly in casual handling and are a genuine shipping-error risk. HPLC plus MS identity, not appearance, is the control.
• Latanoprost has five stereocentres and a defined configuration (9α,11α,15R). A single wrong isomer can collapse FP potency. For ophthalmic-grade material, specify chiral purity and the isomeric profile, not just "≥99% HPLC".
• Bimatoprost is an amide, not an ester. It is routinely lumped with the prostaglandins in trade literature, but it is chemically a prostamide and must be ordered under its own CAS. It has no isopropyl ester to hydrolyse.
• Misoprostol is supplied racemic at the C16 methyl-hydroxy centre. The specification is anchored to the pharmacopoeial standard for the racemate, not to a single enantiomer — a point that is settled at specification stage rather than at receipt.

4. Receptor Pharmacology: EP vs FP — Why the Target Decides the Market

The commercial map of prostaglandin APIs is drawn directly from receptor selectivity. This is not academic detail; it explains why one compound ends up in UNFPA tenders and another in Indian eye-drop generics.

What follows from that table

• EP3 agonism is the obstetric engine. Misoprostol's high EP3 affinity produces the myometrial contraction that underpins cervical ripening, labour induction and PPH control. It is also why misoprostol carries a well-documented GI side-effect profile — EP3 is abundant in the gut.
• EP4 agonism is the vascular engine. Alprostadil's EP4 (with EP3) activity drives the vasodilation used for erectile dysfunction and ductus arteriosus maintenance.
• FP agonism is the ophthalmic engine. FP activation remodels the extracellular matrix of the ciliary body/trabecular meshwork and increases uveoscleral aqueous outflow. It is also the mechanism behind the two well-known cosmetic side effects of ophthalmic prostaglandins — iridal hyperpigmentation and eyelash hypertrichosis — the latter of which was deliberately repurposed into an eyelash-growth indication for Bimatoprost.

5. Misoprostol Deep Dive — The Highest-Volume Prostaglandin API

Misoprostol is the commercial centre of gravity of the entire category. It is a synthetic PGE1 methyl-ester analog with a stabilised core, and it is the only prostaglandin API with genuinely large-scale multi-tenant institutional demand.

The 1% HPMC dispersion — the detail that explains the whole supply chain

A 200 µg misoprostol tablet contains 0.2 mg of active. Weighing that quantity accurately, blend-uniformly, at commercial tablet scale is not practically achievable with neat powder — and the molecule is sensitive to moisture in the solid state. The industry solution is to supply misoprostol as a 1:100 dispersion in HPMC (hydroxypropyl methylcellulose), typically around 1% w/w.

This is why WHO prequalification dossiers for misoprostol tablets frequently name a dispersion API manufacturing site rather than a bulk-powder site. The qualification points that follow for a misoprostol API source are whether the dispersion form is available, at what assay and content-uniformity specification, and with what moisture-protection packaging; neat-powder capability alone does not meet a tablet manufacturer's requirement.

6. Dinoprostone (PGE2) Deep Dive — Obstetric, Thermolabile

Dinoprostone is the natural prostaglandin E2 and a pan-EP agonist. It does one job exceptionally well — ripening the cervix and inducing labour — and it does it as a local agent, in a gel, insert or pessary form, precisely because the free molecule is too unstable for convenient systemic use.

Where the export volume actually goes

Dinoprostone's demand is concentrated in markets with high institutional birth volumes and expanding obstetric protocols — India, Southeast Asia, parts of Africa and Latin America. Because the API is fragile, a meaningful proportion of trade is not "API" in the classic sense but protected intermediates and stabilised presentations. A specification calling for neat PGE2 powder with a long ambient shelf life is written against the molecule's nature; the realistic outcomes are a cold-chain price or a supply gap.

7. Alprostadil (PGE1) Deep Dive — The Stability-Limited Case

Alprostadil is the native prostaglandin E1 — the molecule the PGE1 series is named after, and the one most often wrongly assumed to be the flagship of the family. Commercially it is the opposite: it is the smallest API export volume of the five, precisely because chemistry, not demand, sets the ceiling.

Why the API trade is small — and where it still exists

Because the molecule cannot tolerate the standard API journey, most commercial value sits downstream in the finished injectable, often under cold chain and with a manufacturer's proprietary stabilisation technology. That said, there is a genuine API and key-intermediate trade: buyers who hold their own stabilisation or lyophilisation capability, and CDMOs building alprostadil injectables, do purchase API and advanced intermediates — but the order sizes are modest and the technical dialogue is deep.

8. Latanoprost Deep Dive — The Ophthalmic Volume Leader

Latanoprost is the highest-volume prostaglandin API on the ophthalmic side, and one of the most mature chiral syntheses in the entire prostaglandin class. It is an isopropyl ester prodrug of a 17-phenyl PGF2α analog, delivered as a 0.005% eye drop.

Why latanoprost became the volume leader in ophthalmics

• Cost curve. Its synthesis, while chiral and non-trivial, has had decades of process optimisation. The result is the lowest cost per gram of the ophthalmic prostaglandin group — the decisive factor in a generic market that competes on price.
• Prescriber familiarity. Latanoprost was the first commercial FP-agonist prostaglandin and remains a first-line generic choice in many formularies, which anchors API demand to a stable, high-volume base.
• Generic density. A dense generic manufacturer base — particularly in India — creates the steady, repeating API order flow that a supply chain needs in order to stay efficient.

9. Bimatoprost Deep Dive — Prostamide, Premium Ophthalmic

Bimatoprost is the analytically distinct member of the ophthalmic group: an ethyl amide prostamide rather than an ester prodrug. It carries two commercial indications — glaucoma/ocular hypertension and eyelash hypotrichosis — which gives it a demand profile nothing else in this table has.

Why it commands a premium

Three reasons. First, the amide chemistry is harder and the cost base higher. Second, the eyelash indication opens a market that is not reimbursed glaucoma therapy — a different commercial channel with different price tolerance. Third, the IOP-lowering claim is strong, which supports premium positioning in a market where latanoprost has already compressed prices.

10. Global Export Volume Ranking (China API Supply) ★

The decisive question in this category is which of these five is really moving volume? The ranking below is a qualitative index based on relative cross-border API and intermediate trade activity from Chinese and other Asian supply chains. It is a directional market view, not a published statistical series — but the ordering is stable and the gaps are large.

1. Misoprostol (CAS 59122-46-2) — the volume leader. Driven by WHO essential-medicines status, sustained institutional procurement through UNFPA, WHO and national maternal-health programmes, and a large generic tablet manufacturing base across Africa, South Asia, Southeast Asia and Latin America. Its thermostable, cold-chain-free tablet form is the reason it can reach exactly the markets with the largest maternal-health need. The practical bottleneck on the supply side is not demand but the dispersion-API capability: not every producer can supply a qualified 1:100 HPMC dispersion, and only a small number of sites appear on WHO prequalified dossiers as the API source.
2. Latanoprost (CAS 130209-82-4) — the ophthalmic volume leader. Sustained bulk demand from Indian and other high-volume generic eye-drop manufacturers, supported by a mature chiral synthesis and the lowest cost per gram in the ophthalmic group. Demand is structurally linked to ageing populations and the long-term expansion of generic glaucoma therapy, which makes it the most predictable recurring API order flow in the category. Several Chinese producers hold DMF and CEP filings and EU GMP certification for this molecule, making it a viable alternative to European and Indian sources for regulated markets.
3. Dinoprostone / PGE2 (CAS 363-24-6) — steady obstetric demand, fragile molecule. Institutional obstetric demand in India, Southeast Asia, Africa and Latin America keeps volume respectable, but the thermal instability means a substantial share of trade moves as intermediate or stabilised presentations rather than neat API. Net oil-equivalent API tonnage therefore sits materially below Misoprostol and Latanoprost.
4. Bimatoprost (CAS 155206-00-1) — growing but premium. Stable kilogram-scale export orders with a clear growth trend, driven by both the glaucoma indication and the eyelash-hypotrichosis channel. Higher synthesis complexity and higher cost keep it out of the commodity tier; buyers here are typically formulation developers targeting differentiated or premium ophthalmic lines rather than price-driven generic tender supply.
5. Alprostadil / PGE1 (CAS 745-65-3) — smallest API volume. Counter-intuitively, the compound that names the PGE1 family is the smallest volume mover. Extreme instability forces the value into finished injectables and proprietary stabilisation technologies; API enquiries are smaller, more specialised, and often tied to a buyer who already holds lyophilisation or clathration capability.

11. Second-Tier & Adjacent Prostaglandins Buyers Ask For

Enquiries rarely arrive for a single molecule. Buyers planning an ophthalmic or pulmonary-hypertension portfolio typically ask about a basket. These adjacent APIs are worth knowing because they are frequently bundled into the same RFQ.

12. Manufacturing Difficulty, Stability & HPAPI Handling

Prostaglandin APIs are not bulk commodity chemicals. They are high-potency active pharmaceutical ingredients (HPAPIs) with chiral, multi-step syntheses and aggressive clean-interface requirements. This shapes the price, the minimum order quantity and the freight, long before the regulatory paperwork begins.

Synthesis difficulty — from hardest to most mature

• Dinoprostone and Alprostadil (natural PGE series) — the metabolically fragile core must be assembled and then protected from itself. Yields are modest, the chemistry demands low-temperature and inert-atmosphere operations, and downstream handling must avoid dehydration and isomerisation.
• Bimatoprost — chiral PGF2α framework plus amide formation; the additional chemistry step raises cost, but the product is far more robust than a PGE once formed.
• Misoprostol — the methyl-ester analog route is well established, but the real manufacturing challenge is not synthesis, it is formulation-ready delivery: producing a validated 1:100 HPMC dispersion with acceptable content uniformity.
• Latanoprost — the most optimised of the group. Multiple stereocentres still require chiral control, but decades of process development have produced a genuinely industrial-scale, cost-competitive route.

Stability and storage — the practical differentiator

HPAPI containment — what changes on site

• Occupational exposure limits far below general API defaults. Handling areas need dedicated or segregated rooms, negative-pressure engineering, dust control and closed transfer.
• Analytical capability is part of the deal. Method development for related substances, isomer content and assay at very low concentrations is a specialist service, not a checkbox.
• Warehouse segregation matters more than usual here. Alprostadil and Dinoprostone differ by two hydrogens; the ophthalmic esters differ by an amide bond. Physical segregation plus barcode-level identity control is the correct control, not visual inspection.

13. Documentation, WHO PQ / DMF / CEP & Export Risk

Every prostaglandin API is a regulated pharmaceutical substance. None of them should be declared, packaged or shipped as an ordinary industrial chemical, and the documentation bar is materially higher than for general fine chemicals.

Documentation package to request for a commercial API enquiry

Customs classification — get this right before the container moves

• Prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues are classified in HS heading 2937.50 (US HTS 2937.50.00.00; EU/UK nomenclature 2937500000), within Chapter 29 organic chemicals. The general duty rate in the US and UK schedules for this subheading is 0%.
• Finished medicaments containing prostaglandins fall in Chapter 30, not 2937. A prepared injectable solution or filled eye-drop bottle is classified in 3003 or 3004. Misclassifying a finished dosage form into 2937.50 is one of the most common errors in this product family.
• Distinguish API from intermediate. The properties of the declaration, and sometimes the licensing requirement, differ. Dinoprostone's tendency to move as an intermediate makes this especially relevant.
• Additional national measures can apply on top of the general rate. For example, US Section 301 additional tariffs are applied to specified Chinese-origin chemical goods. The applicable rate depends on the specific product category and the current measure list, and it is confirmed with a customs broker on a per-shipment basis rather than assumed to equal the 0% general rate.

Regulatory and export risk — ranked

1. Misoprostol — highest compliance exposure. Dual-use obstetrical indications, including medical abortion regimens, mean distribution may be restricted to authorised facilities in some jurisdictions, and import authorisation can be refused or delayed. Pre-clear the destination status, obtain written confirmation of the buyer's licence, and never use a generic chemical description on the declaration.
2. Dinoprostone and Alprostadil — highest logistics risk. Cold chain and short stability create real in-transit loss exposure. Risk here is operational rather than political: it shows up as rejected lots and credit claims.
3. Latanoprost, Bimatoprost and the ophthalmic analogs — lowest friction. Established generic supply chains, mature import paths into India and Southeast Asia, and no unusual distribution restrictions. Slower regulatory friction, but a genuinely competitive price environment.
4. All five — HPAPI classification. High-potency handling requirements apply across the board and are a prerequisite, not a differentiator.

14. API Selection Guide for Formulation Projects

Seven criteria generally decide the selection in this family, in the order below.

1. What is the therapeutic area? Obstetric / uterotonic → Misoprostol or Dinoprostone. Gastroprotective → Misoprostol. Vascular or erectile dysfunction → Alprostadil. Ophthalmic IOP-lowering → Latanoprost or Bimatoprost.
2. Can the target market support a cold chain? If no, the PGE-type options narrow sharply: Misoprostol is the only thermostable choice. If yes, Dinoprostone and Alprostadil remain available but carry higher landed cost.
3. Is the volume target price-driven or differentiation-driven? Price-driven generic ophthalmic → Latanoprost. Premium or dual-indication ophthalmic → Bimatoprost.
4. Is WHO prequalification required for an institutional tender? Where it is, API-site prequalification status is decisive — prequalification attaches to specific manufacturing sites and, for misoprostol, to the dispersion form.
5. Which regulatory filings will the dossier cite? The supplier's DMF or CEP status in the destination market matters here, together with confirmation that the filed specification matches the grade in question.
6. What is the realistic minimum order quantity? HPAPI and thermolabile materials often carry practical MOQs driven by campaign scheduling rather than by demand, so a first order fits more naturally into an existing campaign than into a forced small custom batch.
7. Is identity verification built into incoming QC? In this family, every receipt is confirmed by chromatographic and spectroscopic identity, not by label.

Quick decision table

15. Frequently Asked Questions

16. Conclusion

The five prostaglandin APIs in this comparison share one scaffold and almost nothing else. Misoprostol is the volume engine — a thermostable PGE1 analog that is the only member of the family with genuine institutional-scale demand, and the one that rewards a buyer for understanding the HPMC dispersion requirement. Dinoprostone does essential obstetric work but pays a permanent cold-chain tax. Alprostadil, the molecule that gives the PGE1 family its name, is commercially the smallest API of the five because its chemistry, not its medical value, sets the limit.

On the ophthalmic side, Latanoprost is the mature, high-volume, cost-competitive workhorse, and Bimatoprost is the premium, dual-indication differentiator. FP receptor chemistry puts them in an entirely different supply chain from the EP-acting obstetric APIs — a separation that holds at the level of receptor family, dosage form, storage and dossier.

Three practical rules apply across the family. First, identity is confirmed analytically — Alprostadil and Dinoprostone differ by two hydrogens, and Epoprostenol shares a molecular formula with PGE2. Second, logistics are a quality attribute — for the thermolabile APIs an excursion in transit is a rejected lot, and the data-logger requirement belongs in the contract. Third, documentation precedes price — GMP status, DMF or CEP filings, WHO prequalification where tenders require it, and the destination-market import position, which matters most for misoprostol. In this family, the paperwork and the temperature control are the product.